Le Lézard
Classified in: Ebola virus, Business
Subject: SVY

$65 Billion Market in Medical Laboratory Tests

ROCKVILLE, Md., Sept. 5, 2018 /PRNewswire/ -- In vitro diagnostic tests, or non-imaging laboratory tests that doctors use to make critical health decisions, represent a $65 billion and growing healthcare market. Hundreds of companies participate, though key firms such as Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers and Danaher dominate. This according to market research firm Kalorama Information, a New York City-based research firm that focuses on biotechnology and in vitro diagnostics, or IVD. Kalorama just released its 1800+ page market study, The Worldwide Market for In Vitro Diagnostics, 11th Edition.

Kalorama Information Logo.

Why is this market growing? Kalorama says threats to human health continue - obesity, diabetes, cancer, cardiac disease and infectious diseases, worldwide. These situations have created demand for highly specific, sensitive and sometimes expensive tests. IVD companies spend a lot more than other industries on research, and this fuels new testing products. Is there any limit to growth? Kalorama says that there are limits because testing is regulated by governments worldwide, and test reimbursements in developing countries are often reduced. 

"It's a paradox of sorts. As great technologies come out, as new genomics, microfluidics and IT appear, the appetite of world healthcare systems to pay for tests decreases," said Bruce Carlson.  "What's the way around it? Even more innovation, and public pressure for test funding, for starters. But even without any action on the industry's part, demand is fueled by aging world populations and disease trends." 

These specialized tests have come under scrutiny from payers and regulatory authorities. The study balances out regulations and payor information with new product innovations, disease statistics and clinical practice to arrive at market estimates. Kalorama surveys vendors and reviews published facts and medical journals in making assessments. The firm thinks in vitro diagnostics grow at 4% overall ? but that average is brought down by mature industries within IVD. There are biomarker segments that will double in 5-7 years, according to the report.

"Cancer and infectious disease lead growth," said Bruce Carlson, Publisher of Kalorama Information. "But we are closely watching the infectious disease categories in the wake of PAMA cuts and European lab consolidation and payment slowdowns."

Nevertheless, the market for IVD products is in good shape overall, according to the report. The market improved generally since the last edition of Kalorama's worldwide in vitro diagnostics report. 

The next five to ten years or so will see moderate and gradual change in IVD product markets.  IVD manufacturers can expect:

Infectious diseases are a category to watch in IVD, said Carlson. "Chagas, dengue, chikungunya and other emerging infectious diseases, along with the well-known Ebola and Zika virus have brought a reality that tropical infectious diseases know no borders."

But these aren't the only areas where testing is set to grow.

"Every time you hear about a significant health issue in the United States or worldwide, it's likely that testing has a role," Carlson said. "Substance abuse and opioids? Testing is helping there.  Over prescription of antibiotics? Testing is helping there. Reducing hospital stays? There again, testing can aid."

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website: https://www.kaloramainformation.com/.   

Press Contact:                                                         
Bruce Carlson
212 807 2262


SOURCE Kalorama Information

These press releases may also interest you

at 10:15
The Empire State Building (ESB) today announced the details of "ESB Unwrapped" ? its annual gift to New Yorkers, tourists, and fans across the globe this holiday season. The celebration, which takes place throughout November and December, will...

at 10:15
PNC Bank Canada Branch, the Canadian branch of PNC Bank, announced today the launch of commercial card products designed specifically to support Canada-based companies and U.S. companies doing business in Canada. "These new cards streamline the...

at 10:12
The Government of Canada is continuing to invest in the technology and manufacturing of innovative companies to create good middle-class jobs and ensure that Canada punches above its weight in a competitive global market. Today, the Honourable...

at 10:10
CHARLOTTE, N.C., Nov. 14, 2018 /PRNewswire-PRWeb/ -- Levvel, a technology strategy and consulting firm, is happy to announce the rebranding of its subsidiary company, PayStream Advisors, as Levvel Research. The move will broaden Levvel's capabilities...

at 10:09
Suplari, the AI-driven insights platform for procurement and finance, today announced the launch of Suplari Purchasing Intelligence. This new release enables companies to apply Artificial Intelligence (AI) to monitor, analyze and enforce the buying...

at 10:07
Sinfonia Group and F&M Retail today announced a strategic partnership for design and construction management in the North American market. Sinfonia Group will act as F&M Retail U.S. affiliate for the aforementioned activities.  ...

News published on 5 september 2018 at 11:03 and distributed by: